World Tuberculosis (TB) Day, observed annually on March 24, highlights the devastating lives lost due to TB. Despite the fact that 74 million lives have been saved since 2000 due to increased global efforts, there were still 10.6 million TB cases and 1.6 million TB-associated deaths in 2021, according to the World Health Organization (WHO).
The WHO’s TB strategy created in 2014 highlights the targets for 2035. Globally, the number of TB deaths needs to reduce by 95% and the incidence of TB infection by 90%, compared to 2015. To reach these targets, there needs to be a global effort to increase surveillance via testing and vaccinations, especially in low- and middle-income countries. As a result, the global TB test market is forecast to reach $441.8 million by 2030, according to GlobalData’s Mycobacterium Tuberculosis Tests market model.
According to GlobalData’s Mycobacterium Tuberculosis Tests market model, Qiagen held 33.8% of the global TB tests market in 2022, with Oxford Immunotec as second with 14.3%. GlobalData covers interferon-gamma release assays (IGRA) and singleplex nucleic acid amplification tests (NAATs) in the model. However, with more multiplex tests for respiratory diseases being released, there may be an increase in the market share held by multiplex tests in the near future.
